Iasibon (Ibandronic Acid)

Ibandronic acid binds to bone mineral surfaces and is taken up by osteoclasts during bone resorption. Inside the cell it disrupts the mevalonate pathway, leading to osteoclast apoptosis and a consequent reduction in bone breakdown.

The dosing regimen for Iasibon is determined by the prescribing clinician based on the patient’s indication, renal function, and calcium status. The prescriber will select the appropriate infusion schedule and amount.

Safety of ibandronic acid in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Iasibon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iasibon (ibandronic acid) is a potent, once‑monthly or once‑every‑three‑months intravenous bisphosphonate, offering a longer dosing interval than many oral agents. Its efficacy in reducing vertebral fractures is comparable to other IV bisphosphonates, while its safety profile is similar, with renal function and acute phase reactions being the primary considerations.

Iasibon should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the product, and keep it out of direct sunlight until it is prepared for intravenous administration.

Iasibon is given as an intravenous infusion over a short period, typically 15–30 minutes, under the supervision of a qualified healthcare professional. The infusion rate and total dose are set by the prescribing physician according to the approved indication.

Serious risks include acute renal impairment, severe hypocalcaemia, atrial fibrillation, osteonecrosis of the jaw, and rare anaphylactic reactions. Patients should be monitored for signs of renal dysfunction, calcium disturbances, and any unusual cardiac symptoms during and after infusion.

Iasibon is contraindicated in patients with known hypersensitivity to ibandronic acid, severe renal impairment (creatinine clearance <30 mL/min), untreated hypocalcaemia, or active dental or jaw conditions that could predispose to osteonecrosis. Caution is also advised in pregnant or breastfeeding women.